Literature DB >> 15001157

Immunotherapy of melanoma.

Giorgio Parmiani1, Chiara Castelli, Licia Rivoltini, Chiara Casati, Glenn A Tully, Luisa Novellino, Andrea Patuzzo, Diego Tosi, Andrea Anichini, Mario Santinami.   

Abstract

The rationale for immunotherapy of human melanoma is based on the knowledge acquired in the molecular characterization of T cell defined antigens which are recognized in vitro by patients' lymphocytes. Based on this information, active immunotherapy (vaccination) and adoptive immunotherapy trials were conducted in metastatic melanoma patients. This review highlights the most important clinical studies and discuss their limits, in terms of both immune and clinical response considering the formulation of the vaccine (cellular, peptide/protein; DNA, etc.) or the features of immune cells used in adoptive immunotherapy. This new knowledge, along with that of escape mechanisms, should allow to improve significantly the clinical response rate in the immunotherapy of melanoma.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 15001157     DOI： 10.1016/j.semcancer.2003.09.001

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN： 1044-579X            Impact factor:   15.707


  14 in total

1.  Melanoma: Molecular Pathogenesis and Therapeutic Management.

Authors:  Yuxin Liu; M Saeed Sheikh
Journal:  Mol Cell Pharmacol       Date:  2014

Review 2.  Understanding the response to immunotherapy in humans.

Authors:  Ena Wang; Monica C Panelli; Francesco M Marincola
Journal:  Springer Semin Immunopathol       Date:  2005-01-22

3.  Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status.

Authors:  Luca Sigalotti; Alessia Covre; Susan Zabierowski; Benjamin Himes; Francesca Colizzi; Pier Giorgio Natali; Meenhard Herlyn; Michele Maio
Journal:  J Cell Physiol       Date:  2008-05       Impact factor: 6.384

4.  Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells.

Authors:  Robert Besch; Hendrik Poeck; Tobias Hohenauer; Daniela Senft; Georg Häcker; Carola Berking; Veit Hornung; Stefan Endres; Thomas Ruzicka; Simon Rothenfusser; Gunther Hartmann
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

5.  Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells.

Authors:  Andrzej Slominski; Blazej Zbytek; Radomir Slominski
Journal:  Int J Cancer       Date:  2009-03-15       Impact factor: 7.396

Review 6.  Strategies to overcome obstacles to successful immunotherapy of melanoma.

Authors:  F Pandolfi; R Cianci; S Lolli; I S Dunn; E E Newton; T J Haggerty; L A Boyle; J T Kurnick
Journal:  Int J Immunopathol Pharmacol       Date:  2008 Jul-Sep       Impact factor: 3.219

7.  Generation of more effective cancer vaccines.

Authors:  Daniela Fenoglio; Paolo Traverso; Alessia Parodi; Francesca Kalli; Maurizio Zanetti; Gilberto Filaci
Journal:  Hum Vaccin Immunother       Date:  2013-08-26       Impact factor: 3.452

Review 8.  DNA vaccination: using the patient's immune system to overcome cancer.

Authors:  Georg Eschenburg; Alexander Stermann; Robert Preissner; Hellmuth-Alexander Meyer; Holger N Lode
Journal:  Clin Dev Immunol       Date:  2010-12-16

9.  Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients.

Authors:  Alessandra Curioni-Fontecedro; Natko Nuber; Daniela Mihic-Probst; Burkhardt Seifert; Davide Soldini; Reinhard Dummer; Alexander Knuth; Maries van den Broek; Holger Moch
Journal:  PLoS One       Date:  2011-06-27       Impact factor: 3.240

10.  Pigmentation Levels Affect Melanoma Responses to Coriolus versicolor Extract and Play a Crucial Role in Melanoma-Mononuclear Cell Crosstalk.

Authors:  Małgorzata Pawlikowska; Tomasz Jędrzejewski; Andrzej T Slominski; Anna A Brożyna; Sylwia Wrotek
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.